M Ventures reported an active week across its biotech and life sciences tools portfolio, highlighted by fresh funding rounds for Lightcast and STORM Therapeutics. The updates underscore the firm’s continued focus on advanced research platforms and oncology innovation, with new capital aimed at pushing key assets further into commercialization and clinical development.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lightcast, a portfolio company developing the Envisia single-cell analysis platform, secured a $27 million financing led by ARCH Venture Partners with participation from M Ventures and several other investors. The funds are earmarked to support a full commercial launch of the Envisia benchtop system in 2026, expand its range of single-cell functional assays, and scale technical, manufacturing, and software capabilities.
Lightcast also added industry veteran Brad Crutchfield, formerly chief commercial officer at 10x Genomics, as an advisor to its board. His involvement is expected to help refine the company’s commercial go-to-market strategy as it targets use cases in antibody discovery, oncology therapeutics, and cell line development, potentially strengthening the long-term value of M Ventures’ stake.
In oncology, M Ventures highlighted a $56 million Series C financing for portfolio company STORM Therapeutics, which focuses on targeting RNA modifications for cancer treatment. The proceeds are intended to accelerate development of STC-15, described as a first-in-class, oral small-molecule METTL3 inhibitor, and to advance it through ongoing clinical trials.
STORM has already dosed the first patient in a Phase 2 monotherapy study of STC-15 in selected sarcoma indications, marking a key milestone for the program. The funding and trial progress provide greater visibility on STORM’s path in precision oncology and could support future partnering or financing options, enhancing the strategic outlook for M Ventures’ broader portfolio.
Taken together, the week’s developments signal continued momentum for M Ventures in high-impact therapeutic and tools platforms, with new capital and clinical progress positioning its portfolio companies for important commercialization and value-creation milestones ahead.